Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

249
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
249
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.0K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.0K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

14.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
14.0K
Rh Blood Group01:19

Rh Blood Group

2.7K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.7K
Blood Transfusion01:15

Blood Transfusion

2.1K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.1K
Blood Typing01:10

Blood Typing

2.3K
Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancer.

Nature communications·2026
Same author

A Siderophore-Antibiotic Heterodimer Imaging Agent Enables <i>In Vivo</i> PET Imaging of <i>S. aureus</i> Infections.

Journal of medicinal chemistry·2026
Same author

Activation of the NLRP3 inflammasome in osteoclasts is suppressed by a Tmem178-dependent mechanism that restricts Ca<sup>2+</sup> influx.

Science signaling·2026
Same author

Remembering Steven Teitelbaum, scientist, physician, mentor, friend, and family man.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Activation of the noncanonical inflammasome-GSDMD pathway triggers pyroptosis in bone marrow and promotes periosteal bone formation.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Activation of the noncanonical inflammasome-GSDMD pathway triggers pyroptosis in bone marrow and promotes periosteal bone formation.

bioRxiv : the preprint server for biology·2025
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
Same journal

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same journal

A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials.

Nature medicine·2026
Same journal

Blood-based circular RNAs for early diagnosis of Alzheimer's disease.

Nature medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Disorders of Erythrocytes
01:27

Disorders of Erythrocytes

2.0K

Vav3 regulates osteoclast function and bone mass.

Roberta Faccio1, Steven L Teitelbaum, Keiko Fujikawa

  • 1Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, Missouri 63110, USA.

Nature Medicine
|February 16, 2005
PubMed
Summary
This summary is machine-generated.

Researchers identified Vav3 as crucial for osteoclast function and bone density. Vav3 deficiency increases bone mass, offering a potential new target for osteoporosis therapies.

More Related Videos

Immune Compatible Blood Transfusion and Agglutination
02:45

Immune Compatible Blood Transfusion and Agglutination

14.0K
Rh Blood Group
01:19

Rh Blood Group

2.7K

Related Experiment Videos

Last Updated: Jan 10, 2026

Disorders of Erythrocytes
01:27

Disorders of Erythrocytes

2.0K
Immune Compatible Blood Transfusion and Agglutination
02:45

Immune Compatible Blood Transfusion and Agglutination

14.0K
Rh Blood Group
01:19

Rh Blood Group

2.7K

Area of Science:

  • Biochemistry
  • Cell Biology
  • Orthopedics

Background:

  • Osteoporosis is a significant health issue in the elderly, marked by bone loss due to imbalanced bone remodeling.
  • Osteoclast overactivity is a key driver of osteoporosis, leading to reduced bone density and increased fracture risk.

Purpose of the Study:

  • To investigate the role of Vav3, a Rho family guanine nucleotide exchange factor, in osteoclast activation and bone metabolism.
  • To determine if Vav3 deficiency impacts bone density and protects against bone loss.

Main Methods:

  • Studied Vav3-deficient osteoclasts to assess actin cytoskeleton organization, polarization, spreading, and resorptive activity.
  • Examined signaling pathways downstream of M-CSF receptor and alpha(v)beta3 integrin in Vav3-deficient osteoclasts.
  • Analyzed bone mass and response to bone resorption stimuli (PTH, RANKL) in Vav3-deficient mice.
  • Investigated the upstream regulation of Vav3 by Syk tyrosine kinase.

Main Results:

  • Vav3-deficient osteoclasts exhibited impaired actin organization, polarization, spreading, and reduced resorptive capacity.
  • Vav3-deficient mice displayed increased bone mass and were protected from PTH- and RANKL-induced bone loss.
  • Syk tyrosine kinase was identified as a critical upstream regulator of Vav3 in osteoclasts.

Conclusions:

  • Vav3 is essential for osteoclast activation and plays a key role in regulating bone density.
  • Targeting Vav3 presents a promising therapeutic strategy for developing novel anti-osteoporosis treatments.